The plastic healthcare packaging market size is projected to expand from USD 55.60 billion in 2025 and USD 59.99 billion in 2026 to USD 87.74 billion by 2031, registering a CAGR of 7.90% between 2026 to 2031. This report is Segmented by Packaging Type (Bottles & Jars, Blister Packs, Vials & Ampoules, and More), Material (HDPE, LDPE/LLDPE, PP, and More), Product Type (Primary, Secondary, Tertiary), Technology (Injection Molding, and More), End User (Pharmaceutical, Medical Device, Nutraceutical, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Polypropylene is leading resin growth, with a projected CAGR of 12.5%. Its ability to endure autoclave sterilization at 121 °C for 20 minutes and withstand gamma doses up to 50 kGy makes it a preferred choice. Its high heat-deflection temperature enables the re-use of tooling across parenteral closures, syringe barrels, and inhaler bodies, enhancing economies of scale for converters. In 2025, HDPE held 33.45% of the plastic healthcare packaging market, supported by its affordability and moisture barrier properties. However, regulatory measures, such as France's EPR fee on non-recyclable PVC-PVDC blisters, are accelerating the shift toward all-PP structures, further driving polypropylene's growth.
Asia-Pacific is set to lead with a projected 9.8% CAGR from 2026 to 2031. China's National Medical Products Administration, aligning its extractables guidance with ICH Q3E, has expedited approvals for COC vials from Gerresheimer’s Zhangjiagang facility. In India, Lonza's upcoming expansion will add two billion annual capsule shells and closures by late 2026. Southeast Asian nations, spearheaded by Singapore, are incentivizing pharma cleanroom investments with tax credits, encouraging local production of polypropylene syringes and PET inhaler bodies.
Europe maintained a share in the mid-20s percentage range in 2025, bolstered by stringent compliance norms. The Falsified Medicines Directive spurred widespread serialization, while Germany's VerpackG mandates EPR costs on every unit, shifting focus towards recyclability. In France, CITEO's fees on PVC blisters have prompted many generic firms to transition to PP/PET hybrids. While Southern European markets are slower to adopt new materials, they are still investing in code-aggregation hardware to adhere to pan-EU traceability mandates, sustaining demand in the plastic healthcare packaging sector.
Global Plastic Healthcare Packaging Market Trends and Insights
Biologics Boom Increasing Need for High-Barrier Plastic Containers
Monoclonal antibodies, cell therapies, and gene-editing products now represent over 40% of investigational drug filings. These modalities require ultra-low moisture vapor transmission rates, a standard consistently achieved by COC and COP. These resins also eliminate the tungsten leachables associated with molded glass, reducing the risk of protein aggregation during long-term storage. Starting January 2026, the European Pharmacopoeia will implement benchmarks for COC and COP, standardizing extractables testing and streamlining approval processes across Europe. Companies such as West Pharmaceutical Services and Daikyo Seiko are leveraging this regulatory clarity by scaling up production of FluroTec-coated elastomer closures, which ensure over 99% drug-contact neutrality. Additionally, Catalent and Recipharm are enhancing production capabilities by installing blow-fill-seal lines with a capacity of 400 units per minute, incorporating automated particulate inspection to maintain ISO 13485 compliance. These advancements collectively reinforce the growing prominence of polymers in the plastic healthcare packaging market.Home-Healthcare Shift Fueling Demand for Unit-Dose Formats
Healthcare payers in the United States and Europe are incentivizing in-home infusion by offering reimbursements at 30-50% lower rates compared to hospital-based treatments. This trend is driving manufacturers to repackage therapies into prefilled syringes and single-dose blisters. Solutions like Becton Dickinson’s BD Effivax and Gerresheimer’s Gx RTF syringes simplify nursing procedures by eliminating the need for reconstitution, significantly reducing medication errors among elderly patients managing multiple prescriptions. The FDA’s 2024 draft guidance emphasizes the importance of user-friendly packaging, accelerating the adoption of tamper-evident, child-resistant blisters. These developments are creating a sustained demand trajectory for the plastic healthcare packaging market through 2031.Europe Tightens Grip on Single-Use Plastics with New Regulations
Europe's Packaging and Packaging Waste Regulation (PPWR) requires all packaging to be recyclable by 2030 and establishes a 30% recycled-content target for PET by the same year. Although medical packaging has temporary exemptions, producers must provide evidence of no viable alternatives, driving a shift toward monomer blisters. In Germany, pharmaceutical companies are now obligated to fund collection networks, adding costs of EUR 0.05-0.15 per blister pack, which reduces profit margins for generic products. These financial challenges undermine the value proposition of PVC-PVDC laminates, despite their superior barrier properties, potentially limiting growth in the plastic healthcare packaging market beyond 2030.Other drivers and restraints analyzed in the detailed report include:
- Smart NFC-Enabled Packs for Adherence and Anti-Counterfeiting
- Adoption of Cyclic-Olefin Polymers for mRNA Vaccine Vials
- FDA's New Guidelines Heighten Scrutiny on Polymers
Segment Analysis
Vials and ampoules are projected to grow at an 11.8% CAGR from 2026 to 2031, surpassing all other formats in the plastic healthcare packaging market. Pharmaceutical manufacturers increasingly prefer COC and COP vials for high-value biologics due to their ability to prevent delamination during lyophilization cycles and resist breakage during cold-chain logistics. In 2025, bottles and jars accounted for 47.8% of the plastic healthcare packaging market, driven by HDPE's chemical resilience for solid orals and nutraceuticals. However, growth is slowing as payers transition to adherence-friendly blister cards. Serialization mandates from both the EU FMD and the U.S. DSCSA emphasize batch-level traceability, which integrates more effectively into blister webs and unit-dose syringes than bulk bottles, signaling a long-term market shift.Polypropylene is leading resin growth, with a projected CAGR of 12.5%. Its ability to endure autoclave sterilization at 121 °C for 20 minutes and withstand gamma doses up to 50 kGy makes it a preferred choice. Its high heat-deflection temperature enables the re-use of tooling across parenteral closures, syringe barrels, and inhaler bodies, enhancing economies of scale for converters. In 2025, HDPE held 33.45% of the plastic healthcare packaging market, supported by its affordability and moisture barrier properties. However, regulatory measures, such as France's EPR fee on non-recyclable PVC-PVDC blisters, are accelerating the shift toward all-PP structures, further driving polypropylene's growth.
Complete Report Scope:
- By Packaging Type
- Bottles & Jars
- Blister Packs
- Vials & Ampoules
- Pouches & Bags
- Tubes
- Syringes
- Others
- By Material
- HDPE
- LDPE / LLDPE
- PP
- PVC
- PET
- Others
- By Product Type
- Primary Packaging
- Secondary Packaging
- Tertiary Packaging
- By Technology
- Injection Molding
- Blow Molding
- Extrusion
- Thermoforming
- Fill & Seal
- 3D Printing
- By End User
- Pharmaceutical Manufacturers
- Medical Device Manufacturers
- Nutraceutical & Dietary Supplement Manufacturers
- Home Healthcare Providers
- Diagnostic & Clinical Laboratories
- Contract Packaging Organizations
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
In 2025, North America accounted for 38.67% of the revenue, driven by DSCSA deadlines that accelerated blister serialization and NFC-label adoption across prescription portfolios. The U.S. leads the region, supported by Medicare Advantage reimbursements favoring at-home injections. Meanwhile, Canada aligns closely with FDA standards, facilitating smoother cross-border operations. As global sponsors shift focus from Asia, Mexico's contract-drug manufacturing hubs are benefiting, providing a boost to local plastics converters.Asia-Pacific is set to lead with a projected 9.8% CAGR from 2026 to 2031. China's National Medical Products Administration, aligning its extractables guidance with ICH Q3E, has expedited approvals for COC vials from Gerresheimer’s Zhangjiagang facility. In India, Lonza's upcoming expansion will add two billion annual capsule shells and closures by late 2026. Southeast Asian nations, spearheaded by Singapore, are incentivizing pharma cleanroom investments with tax credits, encouraging local production of polypropylene syringes and PET inhaler bodies.
Europe maintained a share in the mid-20s percentage range in 2025, bolstered by stringent compliance norms. The Falsified Medicines Directive spurred widespread serialization, while Germany's VerpackG mandates EPR costs on every unit, shifting focus towards recyclability. In France, CITEO's fees on PVC blisters have prompted many generic firms to transition to PP/PET hybrids. While Southern European markets are slower to adopt new materials, they are still investing in code-aggregation hardware to adhere to pan-EU traceability mandates, sustaining demand in the plastic healthcare packaging sector.
List of Companies Covered in this Report:
- Amcor plc
- AptarGroup Inc.
- Becton Dickinson & Co.
- Berry Global Group
- Catalent
- Comar LLC
- Datwyler Holding
- Gerresheimer
- Huhtamaki Oyj
- KP Pharma (Klockner Pentaplast)
- Nolato
- Plastipak Holdings
- RPC M&H Plastics
- Schott AG (SCHOTT Pharma)
- SGD Pharma
- Tekni-Plex Inc.
- Weener Plastics
- West Pharmaceutical Services
- Wihuri Group (Winpak)
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amcor plc
- AptarGroup Inc.
- Becton Dickinson & Co.
- Berry Global Group
- Catalent Inc.
- Comar LLC
- Datwyler Holding
- Gerresheimer AG
- Huhtamaki Oyj
- KP Pharma (Klockner Pentaplast)
- Nolato AB
- Plastipak Holdings
- RPC M&H Plastics
- Schott AG (SCHOTT Pharma)
- SGD Pharma
- Tekni-Plex Inc.
- Weener Plastics
- West Pharmaceutical Services
- Wihuri Group (Winpak)
